Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Up 522.2% in June

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) was the target of a significant growth in short interest during the month of June. As of June 30th, there was short interest totalling 5,600 shares, a growth of 522.2% from the June 15th total of 900 shares. Based on an average trading volume of 12,100 shares, the short-interest ratio is presently 0.5 days. Currently, 0.1% of the company’s shares are short sold.

Hedge Funds Weigh In On Armata Pharmaceuticals

An institutional investor recently raised its position in Armata Pharmaceuticals stock. SeaCrest Wealth Management LLC lifted its stake in shares of Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) by 80.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 32,777 shares of the company’s stock after acquiring an additional 14,647 shares during the quarter. SeaCrest Wealth Management LLC owned 0.09% of Armata Pharmaceuticals worth $137,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 3.57% of the company’s stock.

Armata Pharmaceuticals Trading Up 1.3 %

Armata Pharmaceuticals stock traded up $0.04 during trading on Friday, reaching $3.04. 2,513 shares of the company were exchanged, compared to its average volume of 15,250. Armata Pharmaceuticals has a 52-week low of $1.07 and a 52-week high of $5.26.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last announced its quarterly earnings results on Tuesday, May 7th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.41). The firm had revenue of $0.97 million during the quarter, compared to analyst estimates of $1.20 million. Analysts forecast that Armata Pharmaceuticals will post -1.9 earnings per share for the current year.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Armata Pharmaceuticals in a report on Thursday.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.